Glenmark Life Sciences Ltd - 543322 - Letter of Offer
DAM Capital Advisors Limited ("Manager to the Offer") has submitted to BSE a copy of Letter of Offer to the Public Shareholders of Glenmark Life Sciences Ltd ("Target Company").09-02-2024
09-02-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript of Earning Call31-01-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of the Q3 FY2023-24 Earnings Call held on 24th January, 2024 on the website of the Company at: https://www.glenmarklifesciences.com/pdf/GLE9320240124150895.mp324-01-2024
Glenmark Life Sciences Results Earnings Call for Q3FY24
Conference Call with Glenmark Life Sciences Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.24-01-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation Q3 - FY 23-2423-01-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release and Management Discussion & Analysis is attached.23-01-2024
Glenmark Life Sciences Ltd - 543322 - Board Meeting Outcome for Unaudited Financial Results For The Third Quarter And Nine Months Ended December 31, 2023
Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that the Board at its meeting held today approved the Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2023. The said meeting of the Board commenced at 03.30 p.m. and concluded at 04:55 p.m. The copy of the said results and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company.23-01-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Life Sciences signs Master Supply Agreement with a leading Japanese Innovator pharmaceutical Company19-01-2024
Glenmark Life Sciences Ltd - 543322 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Wednesday, January 24, 2024 at 8:30 a.m.- 9:30 a.m. (IST), for your information and record.17-01-2024
Glenmark Life Sciences Ltd - 543322 - Closure of Trading Window
As per the ''Code of conduct for Prevention of Insider Trading'' and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has intimated its ''Designated Persons'' regarding the closure of the trading window from December 31, 2023 to January 25, 2024 (both days inclusive) for the purpose of approval of unaudited financial results for the third quarter and nine months ended December 31, 202315-01-2024